Perrigo Company plc (PRGO) has settled Hatch-Waxman litigation relating to Picato (ingenol mebutate) gel, 0.015 percent, 0.05 percent brought by LEO Pharma Inc., LEO Pharma A/S, and LEO Laboratories Limited. Picato gel is indicated for the treatment of actinic keratosis.
Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, “This settlement is another example of long-term investments in our extended topicals strategy. Our R&D and legal teams continue to work hard in bringing to market new generic products that provide savings to patients and healthcare systems.”
(Source: Perrigo Company plc)
